BioMarin to Acquire Alesta Therapeutics for Up to $490 Million

Companies: BioMarin & Alesta Therapeutics · Event Type: Acquisition · Deal Value: $275M Upfront + Up to $215M Milestones · Lead Asset: ALE1 (Oral) · Indication: Hypophosphatasia · Announcement Date: August 18, 2026 Summary BioMarin agreed to acquire privately held Alesta Therapeutics for $275 million…